OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, I
| Current Price | ₹1,377.80 |
|---|---|
| Market Cap | ₹16,144 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | -213 |
| Return on Equity | -1.26% |
| 52-Week Range | ₹1,057.00 – ₹1,925.00 |
| Beta (1Y) | 0.27 |
| Revenue | ₹449 Cr |
|---|---|
| Net Profit | ₹25 Cr |
| EPS (Basic) | ₹2.18 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
1. Contract Development & Manufacturing Organization-100%
Onesource Specialty Pharma Limited is trading at ₹1,377.80, with a market capitalisation of ₹16,144 Cr.
Onesource Specialty Pharma Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Onesource Specialty Pharma Limited has a P/E of -213 and a return on equity of -1.26%.
In Q1 FY27, Onesource Specialty Pharma Limited reported revenue of ₹449 Cr and net profit of ₹25 Cr, with basic EPS of ₹2.18 (consolidated, parsed from the company's exchange filing).